MacroGenics to Participate in Upcoming Investor Conference
MacroGenics, Inc. (MGNX) to participate in the 42nd Annual J.P. Morgan Healthcare Conference with President & CEO, Scott Koenig, M.D., Ph.D., providing a corporate overview on January 11, 2024.
01/08/2024 - 04:30 PM
ROCKVILLE, MD, Jan. 08, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following upcoming investor conference:
42nd Annual J.P. Morgan Healthcare Conference. MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will provide a corporate overview on Thursday, January 11, 2024, at 7:30 am PT. Management will also participate in one-on-one meetings.A webcast of the above presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain an archived replay of this webcast on its website for 30 days after the conference.
About MacroGenics, Inc.
###
What is the upcoming investor conference MacroGenics, Inc. (MGNX) will participate in?
MacroGenics, Inc. (MGNX) will participate in the 42nd Annual J.P. Morgan Healthcare Conference.
Who will provide a corporate overview at the conference for MacroGenics, Inc. (MGNX)?
The President & CEO, Scott Koenig, M.D., Ph.D., will provide a corporate overview.
When will the corporate overview be provided at the conference for MacroGenics, Inc. (MGNX)?
The corporate overview will be provided on Thursday, January 11, 2024, at 7:30 am PT.
Where can the webcast of the presentation be accessed for MacroGenics, Inc. (MGNX)?
The webcast of the presentation may be accessed under 'Events & Presentations' in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm.
How long will the archived replay of the webcast be available for MacroGenics, Inc. (MGNX)?
The archived replay of the webcast will be available on its website for 30 days after the conference.
MGNX Rankings
#2178 Ranked by Stock Gains
MGNX Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Rockville
About MGNX
a career at macrogenics could be waiting for you! please click on "careers" ---------------------------->>> to learn more. macrogenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. macrogenics creates both differentiated molecules that are directed to novel cancer targets, as well as “bio-betters,” which are drugs designed to improve upon marketed medicines. the combination of macrogenics’ technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. these are exciting times at macrogenics and we hope that you will take the opportunity to learn more about our organization, our pipeline and to view our job opportunities!
